SEP 2 2026
Protagonist Therapeutics — rusfertide $PTGX
for polycythemia vera
Accepted MAR 2 2026.
About
Polycythemia vera is a rare blood cancer where the bone marrow overproduces red blood cells, often due to a JAK2 gene mutation, which can lead to dangerous blood thickening. Rusfertide is an injectable peptide that mimics hepcidin, a natural hormone that regulates iron levels and red blood cell production. By controlling iron availability, rusfertide may help reduce excessive red blood cell counts and lower the risk of complications like blood clots.
Pivotal trial
The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on rusfertide
- Rusfertide results in polycythemia vera at European hematology congress - Stock Titan
- Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - ACCESS Newswire
- Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - Corsicana Daily Sun
- Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
- Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits - Fierce Biotech